Download PDF
Aktuelle Neurologie 2016; 43(04): 237-241
DOI: 10.1055/s-0042-102953
Übersicht
© Georg Thieme Verlag KG Stuttgart · New York

Ablagerung von gadoliniumhaltigen Kontrastmitteln im Gehirn nach mehrfacher Anwendung: Konsequenzen für den Einsatz der MRT bei Diagnosestellung und Verlaufsbeurteilung der Multiplen Sklerose?

Accumulation of Gadolinium-based Contrast Agents in the Brain Due to Repetitive Contrast-enhanced MRI: Implications for the Use of MRI in the Diagnosis and Follow-up of Multiple Sclerosis Patients?
C. Lukas
1   Institut für Diagnostische und Interventionelle Radiologie, St. Josef-Hospital, Ruhr-Universität Bochum, Bochum
,
R. Gold
2   Klinik für Neurologie, St. Josef Hospital, Universität Bochum, Bochum
,
J. Fiehler
3   Neuroradiologie, University Medical Center Hamburg-Eppendorf, Hamburg
,
S. Siemonsen
3   Neuroradiologie, University Medical Center Hamburg-Eppendorf, Hamburg
,
J. F. Kleine
4   Abteilung für Neuroradiologie, Technische Universität, München
,
F. Zipp
5   Klinik und Poliklinik für Neurologie, Universitätsmedizin Mainz, Johannes Gutenberg-Universität Mainz, Mainz
,
B. Hemmer
6   Abteilung für Neurologie, Technische Universität, München
,
M. Mühlau
6   Abteilung für Neurologie, Technische Universität, München
› Author Affiliations
Further Information

Publication History

Publication Date:
09 May 2016 (online)

Also available at
   Permissions and Reprints

See also:

Ablagerung von gadoliniumhaltigen Kontrastmitteln im Gehirn nach mehrfacher Anwendung: Konsequenzen für den Einsatz der MRT bei Diagnosestellung und Verlaufsbeurteilung in der Multiplen SkleroseAktuelle Neurologie 2016; 43(08): 522-523
DOI: 10.1055/s-0042-117505

See also:

AntwortAktuelle Neurologie 2016; 43(08): 524-525
DOI: 10.1055/s-0042-117789

Zusammenfassung

Neue Studienergebnisse weisen auf einen Zusammenhang zwischen wiederholten kontrastmittel-unterstützen MRT-Untersuchungen und Ablagerung gadoliniumhaltiger Kontrastmittel im zentralen Nervensystem hin. Ein wesentlicher Faktor hierbei stellt möglicherweise die zum Einsatz kommende Kontrastmittelsubstanzklasse (linear bzw. makrozyklisch) dar. Über die letzten Jahrzehnte hat sich die MRT als ein unverzichtbarer Bestandteil in der Diagnostik, aber auch in der Verlaufsbeurteilung unterschiedlicher Erkrankungen etabliert. Dies gilt im besonderen Maße für chronische Erkrankungen, wie die Multiple Sklerose. Wiederholte MRT-Untersuchungen spielen hier insbesondere durch die zunehmenden Therapieoptionen eine wesentliche Rolle im Verlauf der Erkrankung. Im vorliegenden Artikel werden die derzeit vorhandenen Studienergebnisse über die Ablagerung gadoliniumhaltiger Kontrastmittel zusammengefasst und im Hinblick auf mögliche Konsequenzen für den Einsatz der MRT im Rahmen der Diagnose und insbesondere der Verlaufsbeurteilung der Multiplen Sklerose diskutiert.

Abstract

Recent studies have pointed towards a relationship between repetitive contrast- enhanced magnetic resonance imaging (MRI) and accumulation of gadolinium-based contrast agents. This relationship seems to be dependent on the subclass of contrast agents (linear vs. cyclic) used. Over the past decades, MRI has become one of the most valuable tools in the diagnosis and follow-up of a wide spectrum of disease entities. This holds true especially for chronic diseases such as multiple sclerosis. Given current strategies to establish MRI in treatment decision pathways due to the availability of more potential treatment options, repetitive MRI is frequently performed during the disease course of MS. In this article, we review currently available studies focusing on the accumulation of gadolinium-based contrast agents. Furthermore, consequences that may arise in the context of MR imaging in MS patients are discussed.

Schlüsselwörter

Magnetresonanztomografie - gadoliniumhaltige Kontrastmittel - Gadoliniumablagerung - Multiple Sklerose

Keywords

magnetic resonance imaging - gadolinium accumulation - multiple sclerosis - gadolinium-based contrast agents
 

  • Literatur

  • 1 Kanal E, Tweedle MF. Residual or retained gadolinium: practical implications for radiologists and our patients. Radiology 2015; 275: 630-634
    CrossrefPubMedGoogle Scholar
  • 2 Grobner T. Gadolinium – a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?. Nephrol Dial Transplant 2006; 21: 1104-1108
    PubMedGoogle Scholar
  • 3 Errante Y, Cirimele V, Mallio CA et al. Progressive increase of T1 signal intensity of the dentate nucleus on unenhanced magnetic resonance images is associated with cumulative doses of intravenously administered gadodiamide in patients with normal renal function, suggesting dechelation. Invest Radiol 2014; 49: 685-690
    CrossrefPubMedGoogle Scholar
  • 4 Kanda T, Ishii K, Kawaguchi H et al. High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. Radiology 2014; 270: 834-841
    CrossrefPubMedGoogle Scholar
  • 5 Ginat DT, Meyers SP. Intracranial lesions with high signal intensity on T1-weighted MR images: differential diagnosis. Radiographic 2012; 32: 499-516
    CrossrefPubMedGoogle Scholar
  • 6 Kanda T, Fukusato T, Matsuda M et al. Gadolinium-based contrast agent accumulates in the brain even in subjects without severe renal dysfunction: evaluation of autopsy brain specimens with inductively coupled plasma mass spectroscopy. Radiology 2015; 276: 228-232
    CrossrefPubMedGoogle Scholar
  • 7 McDonald RJ, McDonald JS, Kallmes DF et al. Intracranial gadolinium deposition after contrast-enhanced mr imaging. Radiology 2015; 275: 772-782
    CrossrefPubMedGoogle Scholar
  • 8 Radbruch A, Weberling LD, Kieslich PJ et al. Gadolinium retention in the dentate nucleus and globus pallidus is dependent on the class of contrast agent. Radiology 2015; 275: 783-791
    CrossrefPubMedGoogle Scholar
  • 9 Robert P, Lehericy Sp, Grand S et al. T1-weighted hypersignal in the deep cerebellar nuclei after repeated administrations of gadolinium-based contrast agents in healthy rats: difference between linear and macrocyclic agents. Invest Radiol 2015; 50: 473-480
    CrossrefPubMedGoogle Scholar
  • 10 Kanda T, Osawa M, Oba H et al. High signal intensity in dentate nucleus on unenhanced T1-weighted MR images: association with linear versus macrocyclic gadolinium chelate administration. Radiology 2015; 275: 803-809
    CrossrefPubMedGoogle Scholar
  • 11 Radbruch A, Weberling LD, Kieslich PJ et al. High-signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted images: evaluation of the macrocyclic gadolinium-based contrast agent gadobutrol. Invest Radiol 2015; 50: 805-810
    CrossrefPubMedGoogle Scholar
  • 12 Idee JM, Port M, Dencausse A et al. Involvement of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: an update. Radiol Clin North Am 2009; 47: 855-869 vii
    CrossrefPubMedGoogle Scholar
  • 13 Stojanov DA, Aracki-Trenkic A, Vojinovic S et al. Increasing signal intensity within the dentate nucleus and globus pallidus on unenhanced T1W magnetic resonance images in patients with relapsing-remitting multiple sclerosis: correlation with cumulative dose of a macrocyclic gadolinium-based contrast agent, gadobutrol. Eur Radiol 2016; 26: 807-815
    CrossrefPubMedGoogle Scholar
  • 14 Weberling LD, Kieslich PJ, Kickingereder P et al. Increased signal intensity in the dentate nucleus on unenhanced T1-weighted images after gadobenate dimeglumine administration. Invest Radiol 2015; 50: 743-748
    CrossrefPubMedGoogle Scholar
  • 15 Ramalho J, Castillo M, AlObaidy M et al. High signal intensity in globus pallidus and dentate nucleus on unenhanced T1-weighted MR images: evaluation of two linear gadolinium-based contrast agents. Radiology 2015; 276: 836-844
    CrossrefPubMedGoogle Scholar
  • 16 Roccatagliata L, Vuolo L, Bonzano L et al. Multiple sclerosis: hyperintense dentate nucleus on unenhanced T1-weighted MR images is associated with the secondary progressive subtype. Radiology 2009; 251: 503-510
    CrossrefPubMedGoogle Scholar
  • 17 Absinta M, Rocca MA, Filippi M. Dentate nucleus T1 hyperintensity in multiple sclerosis. AJNR 2011; 32: E120-E121
    CrossrefPubMedGoogle Scholar
  • 18 Janardhan V, Suri S, Bakshi R. Multiple sclerosis: hyperintense lesions in the brain on nonenhanced T1-weighted MR images evidenced as areas of T1 shortening 1. Radiology 2007; 244: 823-831
    CrossrefPubMedGoogle Scholar
  • 19 Brass SD, Chen NK, Mulkern RV et al. Magnetic resonance imaging of iron deposition in neurological disorders. Top Magn Reson Imaging 2006; 17: 31-40
    CrossrefPubMedGoogle Scholar
  • 20 Drayer B, Burger P, Hurwitz B et al. Reduced signal intensity on MR images of thalamus and putamen in multiple sclerosis: increased iron content?. AJR 1987; 149: 357-363
    CrossrefPubMedGoogle Scholar
  • 21 Gutteridge JM. Iron and oxygen radicals in brain. Ann Neurol 1992; 32 (Suppl) S16-S21
    CrossrefPubMedGoogle Scholar
  • 22 LeVine SM. Iron deposits in multiple sclerosis and Alzheimer's disease brains. Brain Res 1997; 760: 298-303
    CrossrefPubMedGoogle Scholar
  • 23 Powell T, Sussman JG, Davies-Jones GA. MR imaging in acute multiple sclerosis: ringlike appearance in plaques suggesting the presence of paramagnetic free radicals. AJNR 1992; 13: 1544-1546
    PubMedGoogle Scholar
  • 24 Shan DE, Pan HC, Ho DM et al. Presence of activated microglia in a high-signal lesion on T1-weighted MR images: a biopsy sample re-examined. AJNR 2007; 28: 602
    PubMedGoogle Scholar
  • 25 Terada H, Barkovich AJ, Edwards MS et al. Evolution of high-intensity basal ganglia lesions on T1-weighted MR in neurofibromatosis type 1. AJNR 1996; 17: 755-760
    PubMedGoogle Scholar
  • 26 Zhou F, Shiroishi M, Gong H et al. Multiple sclerosis: hyperintense lesions in the brain on T1-weighted MR images assessed by diffusion tensor imaging. Journal of magnetic resonance imaging: JMRI 2010; 31: 789-795
    CrossrefPubMedGoogle Scholar
  • 27 Polman CH, Reingold SC, Banwell B et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69: 292-302
    CrossrefPubMedGoogle Scholar
  • 28 Vigeveno RM, Wiebenga OT, Wattjes MP et al. Shifting imaging targets in multiple sclerosis: from inflammation to neurodegeneration. Journal of magnetic resonance imaging: JMRI 2012; 36: 1-19
    CrossrefPubMedGoogle Scholar
  • 29 Barkhof F, Hommes OR, Scheltens P et al. Quantitative MRI changes in gadolinium-DTPA enhancement after high-dose intravenous methylprednisolone in multiple sclerosis. Neurology 1991; 41: 1219-1222
    CrossrefPubMedGoogle Scholar
  • 30 Burnham JA, Wright RR, Dreisbach J et al. The effect of high-dose steroids on MRI gadolinium enhancement in acute demyelinating lesions. Neurology 1991; 41: 1349-1354
    CrossrefPubMedGoogle Scholar
  • 31 Filippi M, Rocca MA. MR imaging of multiple sclerosis. Radiology 2011; 259: 659-681
    CrossrefPubMedGoogle Scholar
  • 32 Kappos L, Moeri D, Radue EW et al. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group. Lancet 1999; 353: 964-969
    CrossrefPubMedGoogle Scholar
  • 33 Fox RJ, Cree BA, De Seze J et al. MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study. Neurology 2014; 82: 1491-1498
    CrossrefPubMedGoogle Scholar
  • 34 Cotton F, Weiner HL, Jolesz FA et al. MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals. Neurology 2003; 60: 640-646
    CrossrefPubMedGoogle Scholar
  • 35 Guttmann CR, Rousset M, Roch JA et al. Multiple sclerosis lesion formation and early evolution revisited: A weekly high-resolution magnetic resonance imaging study. Mult Scler 2015; Online First DOI: 10.1177/1352458515600247.
    PubMedGoogle Scholar
  • 36 Miller DH, Barkhof F, Nauta JJ. Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis. Brain 1993; 116: 1077-1094
    CrossrefPubMedGoogle Scholar
  • 37 Bonzano L, Roccatagliata L, Mancardi GL et al. Gadolinium-enhancing or active T2 magnetic resonance imaging lesions in multiple sclerosis clinical trials?. Mult Scler 2009; 15: 1043-1047
    CrossrefPubMedGoogle Scholar
  • 38 Filippi M, Rocca MA, Arnold DL et al. Use of imaging in multiple sclerosis. In: European Handbook of Neurological Management. Gilhus NE, Brainin MM. ed. Blackwell Publishing; 2011: 35-51
    Google Scholar
  • 39 Freedman MS, Patry DG, GrandʼMaison F et al. Treatment optimization in multiple sclerosis. Can J Neurol Sci 2004; 31: 157-168
    CrossrefPubMedGoogle Scholar
  • 40 Freedman MS, Selchen D, Arnold DL et al. Treatment optimization in MS: Canadian MS Working Group updated recommendations. Can J Neurol Sci 2013; 40: 307-323
    CrossrefPubMedGoogle Scholar
  • 41 Stangel M, Penner IK, Kallmann BA et al. Multiple Sclerosis Decision Model (MSDM): Entwicklung eines Mehrfaktorenmodells zur Beurteilung des Therapie- und Krankheitsverlaufs bei schubförmiger Multipler Sklerose. Akt Neurol 2013; 40: 486-493
    Article in Thieme ConnectPubMedGoogle Scholar
  • 42 Rio J, Castillo J, Rovira A et al. Measures in the first year of therapy predict the response to interferon beta in MS. Mult Scler 2009; 15: 848-853
    CrossrefPubMedGoogle Scholar
  • 43 Dobson R, Rudick RA, Turner B et al. Assessing treatment response to interferon-beta: is there a role for MRI?. Neurology 2014; 82: 248-254
    CrossrefPubMedGoogle Scholar
  • 44 Grand'Maison F, Bhan V, Freedman MS et al. Utility of the Canadian Treatment Optimization Recommendations (TOR) in MS care. Can J Neurol Sci 2013; 40: 527-535
    CrossrefPubMedGoogle Scholar
  • 45 Rio J, Rovira A, Tintore M et al. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients. Mult Scler 2008; 14: 479-484
    CrossrefPubMedGoogle Scholar
  • 46 Sormani MP, Rio J, Tintore M et al. Scoring treatment response in patients with relapsing multiple sclerosis. Mult Scler 2013; 19: 605-612
    CrossrefPubMedGoogle Scholar
  • 47 Simon JH, Li D, Traboulsee A et al. Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers consensus guidelines. AJNR 2006; 27: 455-461
    PubMedGoogle Scholar
  • 48 Wattjes MP, Barkhof F. Diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy using MRI. Curr Opin Neurol 2014; 27: 260-270
    CrossrefPubMedGoogle Scholar
  • 49 Malayeri AA, Brooks KM, Bryant H et al. National Institutes of Health Perspective on Reports of Gadolinium Deposition in the Brain. J Am Coll Radiol 2016; 13: 237-241
    CrossrefPubMedGoogle Scholar